Bank of Botetourt announces first quarter financial results and quarterly cash dividend

HireQuest to Hold First Quarter 2026 Financial Results Conference Call on Tuesday, May 12, 2026

Red River Bancshares, Inc. Reports First Quarter 2026 Financial Results

Microbot Medical® Announces the Addition of Senior Commercial Executive with Proven Track Record to Accelerate Commercial Readiness in Europe, the Middle East, and Asia (EMEA)

Alliance Entertainment to Host Third Quarter Fiscal Year 2026 Results Conference Call on May 14 at 4:30 p.m. Eastern Time

NextNav to Participate in May 2026 Conferences

Spectral AI Wins Small Business Innovator Award at Inaugural Texas Innovation Conference

Barfresh to Announce First Quarter 2026 Results on May 14, 2026

Eos Energy Enterprises Appoints Alessandro Lagi as Chief Financial Officer to Advance American Storage Infrastructure at Scale

Forward Air Awarded on USA TODAY’s America’s Climate Leaders 2026 List

Standard Motor Products, Inc. Releases First Quarter 2026 Results and Quarterly Dividend

Quantum Computing Inc. to Participate in the 21st Annual Needham Technology, Media, & Consumer Conference

Innventure Strengthens Board with Appointment of John Hewitt and Nomination of Catriona Fallon

Alto Ingredients, Inc. to Release First Quarter 2026 Financial Results on May 6, 2026

Safe Harbor Expands Financial Platform with Enhanced Lending Capabilities to Support Cannabis Industry Growth

BJ's Restaurant & Brewhouse Celebrates National Burger Month with New Premium Wagyu Burger

TAT Technologies to Report First Quarter Results on May 20 and Host Webcast

TOMI Environmental Solutions Signs Letter of Intent for a Merger with Carbonium Core, Inc., a U.S.-Based Producer of Nuclear-Grade Graphite for Advanced Reactors and Infrastructure Demands of AI Data Centers

Elektros Unveils High-Impact "Energy Core" Platform as Gasoline Prices Hit Record Highs-Positioning Real Estate Owners to Capture Margin, Protect NOI, and Capitalize on Soaring Energy Costs

Pliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid Tumors